Investigational drug · Phase 2
CDR132L
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Heart Failure.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "CDR132L"
First trial start
2025
Jun 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CDR132L", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "CDR132L" as an intervention, largest first.
- Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial InfarctionPivotal-lookingCompleted
Cardior Pharmaceuticals GmbHIndustry
NCT05350969 · 294 participants · Start Jul 11, 2022 · Primary completion Sep 26, 2024
Drug: CDR132L; Placebo to CDR132L · For: Myocardial Infarction, Acute; Heart Failure, Left Sided
Sites: Prague, Czechia; Ahaus, Germany; Dresden, Germany · 49 sites in all
- A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular HypertrophyPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06979375 · 200 participants (planned) · Start Jun 30, 2025 · Primary completion May 16, 2027
Drug: CDR132L; Placebo · For: Heart Failure
Sites: Concord, Australia; Brisbane, Australia; Adelaide, Australia · 92 sites in all
- A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06979362 · 200 participants (planned) · Start Jun 27, 2025 · Primary completion Nov 16, 2027
Drug: CDR132L; Placebo · For: Heart Failure
Sites: Birmingham, Alabama; Tucson, Arizona; Covina, California · 118 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07656454 · 32 participants (planned) · Start Jun 17, 2026 · Primary completion Dec 31, 2026
Drug: CDR132L (i.v.); CDR132L (s.c.) · For: Healthy Volunteers; Heart Failure
Sites: Berlin, Germany
Cardior Pharmaceuticals GmbHIndustry
NCT04045405 · 28 participants · Start Jun 21, 2019 · Primary completion Jan 31, 2020
Drug: CDR132L · For: Heart Failure
Sites: London, United Kingdom
Cardior Pharmaceuticals GmbHIndustry
NCT05953831 · 0 participants · Start Apr 30, 2024 · Primary completion Sep 30, 2025
Drug: CDR132L; Placebo · For: Heart Failure With Preserved Ejection Fraction
Newest research
PubMed records naming it or its code names, newest first.
- The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.
Bauersachs J, Solomon SD, Anker SD, et al. · Nat Med 2026
- Nanotechnology-driven heart targeting to fulfil the potential of cardiac microRNA therapies.
Hernández-Bellido N, Hernández-Ainsa S, Köhler R, et al. · Int J Pharm 2026
- MiR-132 inhibition improves myocardial strain in a large animal model of chronic left ventricular adverse remodelling.
Batkai S, Spannbauer A, Viereck J, et al. · Eur Heart J Imaging Methods Pract 2025
- Exploring the role of pericardial miRNAs and exosomes in modulating cardiac fibrosis.
Schoettler FI, Fatehi Hassanabad A, Jadli AS, et al. · Cardiovasc Pathol 2024
- Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial.
Bauersachs J, Solomon SD, Anker SD, et al. · Eur J Heart Fail 2024
- Different Effects on Protein Expression of CDR132L, an Antisense Inhibitor of miR-132, and Standard Therapies for Myocardial Infarction.
Iborra-Egea O, Aimo A, Bayes-Genis A · Front Cardiovasc Med 2022
Also in development for Heart Failure
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- HiCM-188 therapyPhase 32 trials
HELP Therapeutics Co., Ltd. · Heart Failure
- Qishen Yiqi Dripping Pills 2 bagsPhase 32 trials
Tasly Pharmaceutical Group Co., Ltd · Heart Failure, Chronic Heart Failure With Preserved Ejection Fraction
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- AZD3427Phase 21 trial
AstraZeneca · Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.